Breast cancer treatment costs highest among young women with metastic cancer

June 10, 2020

(CHAPEL HILL, N.C., June 10, 2020) Cancer's untold toll may be a financial one, especially among young women fighting advanced breast cancer.

New research by the University of North Carolina at Chapel Hill shows much higher costs for treating metastatic breast cancer patients than for earlier-stage cancer patients or those without cancer.

The findings, published in the journal Breast Cancer Research and Treatment, revealed the largest expected costs were among women age 18-44. Breast cancer in younger women is typically diagnosed at more advanced stages, is more aggressive and less responsive to treatment.

"Our results highlight the tremendous cost burden associated with metastatic breast cancer among working-age women, particularly during the years after initial treatment of metastatic disease as well as at the end of life," said study co-author Stephanie Wheeler, Ph.D., MPH, professor of health policy and management at the Gillings School of Global Public Health and researcher at the Center for Health Promotion and Disease Prevention.

For example, among women aged 18-44, the incremental average monthly cost of treating metastatic breast cancer were $4,463 compared to monthly costs of $2,418 for treating stage 1 cancer. Among other age groups the treatment costs for advanced cancer were not statistically different.

Women living in North Carolina and treated for breast cancer between 2003-2014 were included in the study that was funded by the U.S. Centers for Disease Control and Prevention.

In the study group, 4,806 had metastatic breast cancer, meaning their cancer had spread to other parts of the body, and 21,772 had non-metastatic cancer. The patient data was collected in a cancer registry coordinated by the Lineberger Comprehensive Cancer Center.

Using statistical modeling based on insurance claims data, researchers estimated medical costs for patients with metastatic breast cancer.

For comparison, they also estimated costs for patients with earlier-stage breast cancer and 109,631 women with no cancer who were in the same age group, from the same county of residence, and who had the same type of health insurance.

For women with metastatic breast cancer where the five-year survival rate is only 26.3% compared to 98.8% for localized cancer, treatment continues for longer, and it includes end-of-life care. These factors contribute to the high medical costs associated with metastatic breast cancer, which can be a financial burden for women and their families.

The finding that medical costs are higher for younger and middle age women may reflect their desire for more aggressive treatment and willingness to pay for additional months of life, researchers said, or it may reflect breakdowns in shared decision making between patients and practitioners, leading to treatments with minimal financial and health benefits for patients.

"Our results suggest that we spend nearly twice as much in the last year of life for women that die of breast cancer compared to other causes of death," said study lead author Justin Trogdon, Ph.D., a professor of health policy and management at Gillings School of Global Public Health and researcher at the Center for Health Promotion and Disease Prevention.

"We should work to ensure that end-of-life spending for metastatic breast cancer represents women's preferences and is of high value," said Trogdon, a health economist.

By identifying the age groups and phases of care where medical costs are the highest, the results of this study may inform decision makers about where to invest resources, for example, which groups of patients may be in need of extra financial or psychological support.

The study can also inform future research into how to improve metastatic breast cancer treatment for populations or treatment phases that are currently associated with the highest medical costs.

University of North Carolina at Chapel Hill

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to